Australian Clinical Labs Ltd (AU:ACL) has released an update.
JPMorgan Chase & Co. and its affiliates have reported a significant increase in their voting power in Australian Clinical Labs Ltd, from 8.53% to 11.95%, due to recent changes in their shareholding. This change in the substantial holder’s interest occurred on September 12, 2024, and includes securities lending agreements and purchases by J.P. Morgan entities. Such a substantial change in shareholding could suggest strategic movements within the company’s investor base.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
